UBS Top Stocks to Buy Working for Cancer Cures
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off that may provide investors some incredible outsized gains over the rest of…
New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors should follow…
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Wednesday, February 26, 1014. The include LinkedIn, Safeway, NII Holdings, Rangold Resources and EP Energy.
24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. By and large, short sellers shied away from these stocks in late January.
Before the markets opened Wednesday morning, drug giant Merck & Co. reported fourth-quarter and full-year 2013 results that failed to dazzle. But shares traded higher in the premarket session.
Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across the board.…
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this…
Biotechnology was an incredible performer in 2013. The analysts at J.P. Morgan think that the huge outperformance may lessen going forward but can stay intact. They think the fundamental backdrop is very…
ThinkstockAny time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from close to…
ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated…
August 21, 2013: Markets opened mixed this morning as traders and investors waited for the afternoon’s release of the July FOMC meeting minutes. Existing home sales rose more than expected in July.…
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company has now…
U.S. equity markets opened higher this morning following an unexpected 0.25% cut in Australia’s key interest rate to a new level of 2.75%. Japan’s Nikkei reopened today after a two-day holiday and…
These are the top analyst downgrades, cautious research notes and stocks to sell from Wall Street for Tuesday, May 7, 2013. They include AIG, Coach, J.C. Penney, T-Mobile US and Tiffany.